Polypoidal choroidal vasculopathy (PCV) is a subtype of exudative age-related macular degeneration (AMD) that is most prevalent in Asian populations but is becoming increasingly recognized in populations around the world.1-3 The importance of recognizing PCV is that it is a subtype of exudative AMD that has been associated with resistance to antivascular endothelial growth factor (anti-VEGF) injections, which has become standard treatment for most cases of active exudative AMD.1,2 Therefore, finding a good treatment option for PCV would benefit many patients around the world.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kokame GT, Kim JE. Treatment for a Subtype of Exudative Macular Degeneration—Another Mountain Climbed. JAMA Ophthalmol. Published online July 16, 2020. doi:10.1001/jamaophthalmol.2020.2421
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: